Evaluation of platelet transfusion clinical trials

British Journal of Haematology

Volumn 153, Issue 4, 2011, Pages 529-531

  Corash, Laurence ^a   Sherman, Claire D ^a  

^a CERUS CORPORATION   (United States)

Author keywords

Clinical trials; Pathogen inactivation; Platelets; Transfusion

Indexed keywords

APHERESIS; BLEEDING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; HEMOSTASIS; HUMAN; LETTER; PRIORITY JOURNAL; SAFETY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

BLOOD PLATELETS; BLOOD PRESERVATION; CLINICAL TRIALS AS TOPIC; HEMOSTASIS; HUMANS; PLATELET TRANSFUSION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79954995159     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08413.x     Document Type: Letter

References (10)

1. Cazenave, J.P., Waller, C., Mendel, I., Kientz, D., Kandel, G., Raidot, J.P., Wiesel, M.L., Laforet, M. & Isola, H. (2008) Clinical experience with pathogen inactivation of platelet components for transfusion support. In: Progress and Challenges in Transfusion Medicine, Hemostasis and Hemotherapy (ed. by R.E. Scharf ), pp. 248-263. Karger, Freiburg.
2. Kerkhoffs, J.H., Novotny, V.M., Te Boekhorst, P.A.W., Schipperus, M.R., Zwaginga, J.J., van Pampus, L., van Putten, W.L., Huijgens, P.C., Brand, A. & van Rhenen, D.J. (2009) Clinical effectiveness and safety of pooled, random donor platelet concentrates, leukoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients. Transfusion, 49, 2A.
3. Kerkhoffs, J.L., van Putten, W.L.J., Novotny, V.M.J., Te Boekhorst, P.A.W., Schipperus, M.R., Zwaginga, J.J., van Pampus, L.C.M., de Greef, G.E., Luten, M., Huijgens, P.C., Brand, A. & van Rhenen, D.J. (2010) Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solutions with and without pathogen reduction. British Journal Haematology, 150, 209-217.
4. McCullough, J., Vesole, D.H., Benjamin, R.J., Slichter, S.J., Pineda, A., Snyder, E., Stadtmauer, E.A., Lopez-Plaza, I., Coutre, S., Strauss, R.G., Goodnough, L.T., Fridey, J.L., Raife, T., Cable, R., Murphy, S., Howard, F., Davis, K., Lin, J.S., Metzel, P., Lin, L., Koutsoukos, A., Corash, L., Buchholz, D.H. & Conlan, M.G. (2004) Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood, 104, 1534-1541.
5. Osselaer, J.C., Cazenave, J.P., Lambermont, M., Garraud, O., Hidajat, M., Barbolla, L., Tardivel, R., Defoin, L., Waller, C., Mendel, I., Raidot, J.P., Kandel, G., De Meuter, R., Fabrigli, P., Dehenau, D., Arroyo, J.L., Padron, F., Gouezec, H., Corral, M., Jacquet, M., Sundin, D., Lin, L. & Corash, L. (2008a) An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sanguinis, 94, 315-323.
6. Osselaer, J.C., Messe, N., Hervig, T., Bueno, J.L., Castro, E., Espinosa, A., Accorsi, P., Junge, K., Jacquet, M., Flament, J. & Corash, L. (2008b) A prospective observational cohort safety study of 5, 106 platelet transfusions using components prepared with photochemical pathogen inactivation treatment. Transfusion, 48, 1061-1071.
7. Osselaer, J.C., Doyen, C., Defoin, L., Debry, C., Goffaux, M., Messe, N., Hooydonk, M.V., Bosly, A., Lin, J.S., Lin, L. & Corash, L. (2009) Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion, 49, 1412-1422.
8. Slichter, S.J., Davis, K., Enright, H., Braine, H., Gernsheimer, T., Kao, K., Kickler, T., Lee, E., McFarland, J., McCullough, J., Rodey, G., Schiffer, C.A. & Woodson, R. (2005) Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood, 105, 4106-4114.
9. Slichter, S.J., Kaufman, R.M., Assman, S.F., McCullough, J., Triulzi, D.J., Strauss, R.G., Gernsheimer, T.B., Ness, P.M., Brecher, M.E., Josephson, C.D., Konkle, B.A., Woodson, R.D., Ortel, T.L., Hillyer, C.D., Skerrett, D.L., McCrae, K.R., Sloan, S.R., Uhl, L., George, J.N., Aquino, V.M., Manno, C.S., McFarland, J.G., Hess, J.R., Leissinger, C. & Granger, S. (2010) Dose of prophylactic platelet transfusios and prevention of hemorrhage. New England Journal of Medicine, 362, 600-613.
10. Snyder, E., McCullough, J., Slichter, S.J., Strauss, R.G., Lopez-Plaza, I., Lin, J.S., Corash, L. & Conlan, M.G. (2005) Clinical safety of platelets photochemically treated with amotoslaen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion, 45, 1864-1875.